Bain Capital Life Sciences Investors, LLC
Position in OLMA — Olema Pharmaceuticals, Inc.
CIK 1703031
Boston, MA
Position in OLMA
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$88,636,464
-$22,789,514 QoQ
Shares Held
7,085,249
-5.2% QoQ
Ownership
8.10%
of shares outstanding
% of Portfolio
5.27%
of 13F equity value
Holder Rank
#4
of 182 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in OLMA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Bain Capital Life Sciences Investors, LLC holds $1,318,022,438 across 17 Biotechnology names. OLMA ranks #6 (6.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KLRA |
Kailera Therapeutics, Inc.
|
22,583,268 | $497,509,394 | |
| 2 | NAMS |
NewAmsterdam Pharma Co N.V.
|
3,906,565 | $131,141,499 | |
| 3 | SVRA |
Savara Inc
|
17,600,621 | $108,419,825 | |
| 4 | SLDB |
Solid Biosciences Inc.
|
9,808,819 | $97,990,101 | |
| 5 | PHVS |
Pharvaris N.V.
|
2,675,509 | $92,519,101 | |
| 6 | OLMA |
Olema Pharmaceuticals, Inc.
This page
|
7,085,249 | $88,636,464 | |
| 7 | COAG |
Hemab Therapeutics Holdings, Inc.
|
1,650,000 | $60,604,500 | |
| 8 | CABA |
Cabaletta Bio, Inc.
|
17,241,445 | $53,620,893 |
All Filings in OLMA
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $88,636,464 | 7,085,249 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $111,425,978 | 7,473,238 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $212,716,025 | 8,508,641 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $67,002,309 | 6,843,954 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $29,155,244 | 6,843,954 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $25,733,267 | 6,843,954 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $43,551,347 | 7,470,214 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||